Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
Apply
RBN-2397
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step